Estimated dopamine D2 receptor occupancy and remission in schizophrenia: Analysis of the catie data

Sho Moriguchi, Robert Bies, Gary Remington, Takefumi Suzuki, David C. Mamo, Koichiro Watanabe, Masaru Mimura, Bruce G. Pollock, Hiroyuki Uchida

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In treating schizophrenia, 65% to 80% occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms and cognitive impairments. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain clinical response. The data set from phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial was reappraised. Thirty patients receiving risperidone (12 patients), olanzapine (12 patients), or ziprasidone (6 patients) fulfilled the following definition of remission and were included: a score of 3 or less on the 8 specific items in the Positive and Negative Syndrome Scale (ie, P1, P2, P3, N1, N4, N6, G5, and G9; adopted from Andreasen et al, 2005) at the initial assessment and months 1, 2, and 6. Peak and trough D2 receptor occupancy levels at month 6 were estimated from plasma antipsychotic concentrations using population pharmacokinetic analysis and our D2 prediction model. Estimated mean ± SD peak and trough D2 receptor occupancy levels at month 6 were 70.3% ± 9.8% and 60.5% ± 20.2%, respectively; among these individuals, 46.7% (14 patients) did not achieve continuous blockade of 65% or greater (ie, trough D2 occupancy of

Original languageEnglish (US)
Pages (from-to)682-685
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume33
Issue number5
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Dopamine D2 Receptors
Schizophrenia
olanzapine
Antipsychotic Agents
Clinical Trials, Phase I
Risperidone
Pharmacokinetics
Therapeutics
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Estimated dopamine D2 receptor occupancy and remission in schizophrenia : Analysis of the catie data. / Moriguchi, Sho; Bies, Robert; Remington, Gary; Suzuki, Takefumi; Mamo, David C.; Watanabe, Koichiro; Mimura, Masaru; Pollock, Bruce G.; Uchida, Hiroyuki.

In: Journal of Clinical Psychopharmacology, Vol. 33, No. 5, 10.2013, p. 682-685.

Research output: Contribution to journalArticle

Moriguchi, S, Bies, R, Remington, G, Suzuki, T, Mamo, DC, Watanabe, K, Mimura, M, Pollock, BG & Uchida, H 2013, 'Estimated dopamine D2 receptor occupancy and remission in schizophrenia: Analysis of the catie data', Journal of Clinical Psychopharmacology, vol. 33, no. 5, pp. 682-685. https://doi.org/10.1097/JCP.0b013e3182979a0a
Moriguchi, Sho ; Bies, Robert ; Remington, Gary ; Suzuki, Takefumi ; Mamo, David C. ; Watanabe, Koichiro ; Mimura, Masaru ; Pollock, Bruce G. ; Uchida, Hiroyuki. / Estimated dopamine D2 receptor occupancy and remission in schizophrenia : Analysis of the catie data. In: Journal of Clinical Psychopharmacology. 2013 ; Vol. 33, No. 5. pp. 682-685.
@article{1fd4bfcf039e478dbb5e9aa9b0bac4d9,
title = "Estimated dopamine D2 receptor occupancy and remission in schizophrenia: Analysis of the catie data",
abstract = "In treating schizophrenia, 65{\%} to 80{\%} occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms and cognitive impairments. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain clinical response. The data set from phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial was reappraised. Thirty patients receiving risperidone (12 patients), olanzapine (12 patients), or ziprasidone (6 patients) fulfilled the following definition of remission and were included: a score of 3 or less on the 8 specific items in the Positive and Negative Syndrome Scale (ie, P1, P2, P3, N1, N4, N6, G5, and G9; adopted from Andreasen et al, 2005) at the initial assessment and months 1, 2, and 6. Peak and trough D2 receptor occupancy levels at month 6 were estimated from plasma antipsychotic concentrations using population pharmacokinetic analysis and our D2 prediction model. Estimated mean ± SD peak and trough D2 receptor occupancy levels at month 6 were 70.3{\%} ± 9.8{\%} and 60.5{\%} ± 20.2{\%}, respectively; among these individuals, 46.7{\%} (14 patients) did not achieve continuous blockade of 65{\%} or greater (ie, trough D2 occupancy of",
author = "Sho Moriguchi and Robert Bies and Gary Remington and Takefumi Suzuki and Mamo, {David C.} and Koichiro Watanabe and Masaru Mimura and Pollock, {Bruce G.} and Hiroyuki Uchida",
year = "2013",
month = "10",
doi = "10.1097/JCP.0b013e3182979a0a",
language = "English (US)",
volume = "33",
pages = "682--685",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Estimated dopamine D2 receptor occupancy and remission in schizophrenia

T2 - Analysis of the catie data

AU - Moriguchi, Sho

AU - Bies, Robert

AU - Remington, Gary

AU - Suzuki, Takefumi

AU - Mamo, David C.

AU - Watanabe, Koichiro

AU - Mimura, Masaru

AU - Pollock, Bruce G.

AU - Uchida, Hiroyuki

PY - 2013/10

Y1 - 2013/10

N2 - In treating schizophrenia, 65% to 80% occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms and cognitive impairments. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain clinical response. The data set from phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial was reappraised. Thirty patients receiving risperidone (12 patients), olanzapine (12 patients), or ziprasidone (6 patients) fulfilled the following definition of remission and were included: a score of 3 or less on the 8 specific items in the Positive and Negative Syndrome Scale (ie, P1, P2, P3, N1, N4, N6, G5, and G9; adopted from Andreasen et al, 2005) at the initial assessment and months 1, 2, and 6. Peak and trough D2 receptor occupancy levels at month 6 were estimated from plasma antipsychotic concentrations using population pharmacokinetic analysis and our D2 prediction model. Estimated mean ± SD peak and trough D2 receptor occupancy levels at month 6 were 70.3% ± 9.8% and 60.5% ± 20.2%, respectively; among these individuals, 46.7% (14 patients) did not achieve continuous blockade of 65% or greater (ie, trough D2 occupancy of

AB - In treating schizophrenia, 65% to 80% occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms and cognitive impairments. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain clinical response. The data set from phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial was reappraised. Thirty patients receiving risperidone (12 patients), olanzapine (12 patients), or ziprasidone (6 patients) fulfilled the following definition of remission and were included: a score of 3 or less on the 8 specific items in the Positive and Negative Syndrome Scale (ie, P1, P2, P3, N1, N4, N6, G5, and G9; adopted from Andreasen et al, 2005) at the initial assessment and months 1, 2, and 6. Peak and trough D2 receptor occupancy levels at month 6 were estimated from plasma antipsychotic concentrations using population pharmacokinetic analysis and our D2 prediction model. Estimated mean ± SD peak and trough D2 receptor occupancy levels at month 6 were 70.3% ± 9.8% and 60.5% ± 20.2%, respectively; among these individuals, 46.7% (14 patients) did not achieve continuous blockade of 65% or greater (ie, trough D2 occupancy of

UR - http://www.scopus.com/inward/record.url?scp=84883817566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883817566&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3182979a0a

DO - 10.1097/JCP.0b013e3182979a0a

M3 - Article

C2 - 23899638

AN - SCOPUS:84883817566

VL - 33

SP - 682

EP - 685

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -